Clinical trials

Obesity may contribute to neck pain, altered cervical posture, and impaired cervical function through increased mechanical loading, changes in body alignment, and reduced muscle performance. Although laparoscopic sleeve gastrectomy can produce substantial weight loss, its effects on cervical posture and neck-related function have not been studied comprehensively. This prospective, single-center study will include approximately 25 adults who are already scheduled to undergo laparoscopic sleeve gastrectomy as part of their routine clinical care. The decision to perform surgery and the surgical procedure itself will not be assigned or modified by the study. Participants will be evaluated before surgery and at 3, 6, and 12 months after surgery. Study assessments will include neck-related disability, neck pain intensity, quality of life, cervical range of motion, cervical muscle strength and endurance, and cervical joint position sense. Existing preoperative lateral cervical radiographs will be reviewed, and a lateral cervical radiograph will be obtained at the 12-month follow-up to assess cervical spinal alignment. The primary outcome will be the change in Neck Disability Index scores across the scheduled study assessments. The study aims to determine whether weight loss following laparoscopic sleeve gastrectomy is associated with changes in cervical posture, neck pain, and cervical function.

The gluteus maximus overlies the piriformis muscle and forms a broad fascial interface with it. Restricted movement, increased tension, or adhesions between these tissue layers may contribute to persistent buttock pain in piriformis syndrome. Interfascial hydrodissection is an ultrasound-guided procedure in which fluid is introduced between the gluteus maximus and piriformis muscles to gently separate restricted fascial planes, improve tissue gliding, reduce local mechanical irritation, and potentially modulate nociceptive input from pain-sensitive nerve endings within or adjacent to the fascial interface. The goal of this clinical trial is to learn whether adding ultrasound-guided interfascial hydrodissection to a piriformis injection provides better pain relief and improves function in adults with piriformis syndrome. Piriformis syndrome can cause buttock pain that may spread to the back of the thigh or leg. Interfascial hydrodissection is a procedure in which fluid is injected between the gluteus maximus and piriformis muscles. The fluid gently separates the tissue layers and may help them move more freely. The main questions this trial aims to answer are: * Does adding interfascial hydrodissection to a piriformis injection lower overall pain more than the piriformis injection alone at 3 months after treatment? * Does it provide greater improvement in pain at earlier follow-up visits, hip-related function, and overall recovery? All participants will first receive one ultrasound-guided local anesthetic injection into the piriformis muscle. The early pain response will help support the diagnosis, and the same injection will serve as the common treatment received by both groups. Participants whose pain improves by at least 50 percent will be randomly assigned to either continue with the piriformis injection alone or receive additional interfascial hydrodissection. After the 1-week assessment, participants in both groups will begin the same home-based piriformis stretching program. Participants will: * Receive one ultrasound-guided piriformis injection and, depending on group assignment, may also receive interfascial hydrodissection * Have follow-up assessments later on the treatment day and at 1 week, 1 month, and 3 months * Follow the same home-based stretching program after the 1-week assessment * Report their pain, daily function, overall improvement, pain medicine use, additional treatment needs, and any side effects

This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.

Our study was planned as a prospective observational study aiming to compare the post-intervention recovery process between patients with carpal tunnel syndrome (CTS) and diabetes mellitus and patients with idiopathic carpal tunnel syndrome without diabetes mellitus. Patients who presented to the Physical Medicine and Rehabilitation outpatient clinic with clinical symptoms consistent with carpal tunnel syndrome and who were diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological findings and who received corticosteroid + local anesthetic injection will be included in the study. Data from patients who meet the inclusion and exclusion criteria will be included in the study. Patients' demographic and clinical data will be recorded. Records will be taken before treatment and at 4 and 12 weeks after treatment.

The goal of this clinical trial is to investigate the efficacy of mesotherapy in patients with lateral epicondylitis and to determine whether it is as effective as extracorporeal shock wave therapy (ESWT). Is mesotherapy an effective method in patients with lateral epicondylitis? Researchers will compare Mesotherapy to extracorporeal shock wave therapy (ESWT) in patient with Lateral epicondylitis. Patients will be randomly assigned to either the Mesotherapy group or the ESWT group using a closed envelope method. * Group 1 (Mesotherapy group): Patients will receive a total of 5 sessions of mesotherapy, with one session every 7 days. * Group 2 (ESWT group): Patients will receive a total of 5 sessions of Extracorporeal Shock Wave Therapy (ESWT), with one session every 7 days. Patients will be assessed at three time points: before treatment, 30 minutes after the completion of the treatment, and 12 weeks after the completion of the treatment

Sarcopenia is the loss of muscle mass due to aging, which consequently leads to a decline in muscle function. It is considered an independent risk factor for falls and fractures, disability, postoperative complications, and mortality. Rotator cuff tears are known to be influenced by systemic diseases such as diabetes, hypercholesterolemia, thyroid disorders, and osteoporosis. The aim of our study is to investigate whether there is a relationship between sarcopenia and rotator cuff tears, and if so, to determine the location and type of the tear.